Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients with Ovarian or Breast Cancer.

Millennium Pharmaceuticals, Inc0 个研究点目标入组 191 人开始时间: 2012年7月30日最近更新: 2022年4月19日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Millennium Pharmaceuticals, Inc
入组人数: 191

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Female

入选标准

•1. Female patients 18 years or older.
•2. Previously treated, metastatic or locally recurrent malignancy with 1 of the 2 following diagnoses, which has been confirmed histologically or cytologically: a) adenocarcinoma of the breast (phase 1 only); or b) OC, defined to include recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (phases 1 and 2).
•3. Patients with breast cancer must have received prior treatment with at least 1 but no more than 4 prior chemotherapy regimens for locally recurrent or metastatic disease, not including regimens received in the neoadjuvant and/or adjuvant setting.
•4. In the phase 1 portion of the study, patients with breast cancer must have measurable disease (per RECIST, version 1.1; see Section 15.3 of the protocol).
•5. No antineoplastic therapy or radiotherapy within the 3 weeks before enrollment (2 weeks for regimens with recovery expected within 7 to 14 days). The patient must have recovered (ie, = Grade 1 toxicity or patient’s baseline status, except alopecia) from all treatment related toxicities and must have evidence of PD or persistent disease. The patient must have experienced no more than Grade 2 non-hematologic toxicity attributed to a prior taxane therapy. No hormonal therapy except hormone replacement therapy or birth control medications.
•6. ECOG performance status (PS) of 0 or 1 (refer to Section 15.1 of the protocol).
•7. Adequate bone marrow function as defined by:
•Absolute neutrophil count (ANC) = 1,500 cells/mm3 (without need for growth factor support)
•Platelet count = 100,000 cells/mm3 (without need for transfusion or growth factor support)
•Hemoglobin level = 9 g/dL
•8. Adequate liver function as defined by:
•Bilirubin < 1.5 times the upper limit of normal (ULN)
•Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x ULN (= 5 x ULN if due to liver metastases)
•serum albumin greater than the lower limit of normal (LLN)
•9. Adequate renal function as defined by:
•Creatinine clearance = 30 mL/minute (can be calculated using serum creatinine value; see Section 15.2 of the protocol)
•10. Patients who:
•Are postmenopausal for at least 1 year before the screening visit, OR
•Are surgically sterile, OR
•If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the ICF through 30 days after the last dose of study drug, or agree to completely abstain from heterosexual intercourse
•11. The patient or the patient’s legal representative is able to provide written informed consent. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
•12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
•13. Suitable venous access for the study-required blood sampling.
•Specific Inclusion Criteria for Patients with Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer:
•14. Prior treatments must have included a platinum and a taxane. The most recent treatment regimen (administered prior to enrollment) need not be a platinum containing or a taxane containing regimen.
•Recurrent disease must be documented within 12 months after discontinuation of platinum therapy, based on RECIST or GCIG CA-125 crit

排除标准

•Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
•1. Prior treatment with an Aurora A targeted agent (including alisertib).
•2. Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of alisertib and during the study. Major prohibited enzyme inducers include the following:
•carbamazepine
•phenobarbital
•rifapentine
•St. John's wort
•3. Treatment with more than 4 cytotoxic chemotherapy treatment regimens in the metastatic setting. A cytotoxic agent is defined as any agent that targets the genetic, mitotic, and/or metabolic pathways of dividing cells, resulting in toxicity to the bone marrow and/or gastrointestinal mucosa. A chemotherapy regimen is defined as 1 or more agents used continuously or discontinuously (ie, allowing a break or chemotherapy holiday) without the addition of a new agent. A regimen administered pre-operatively and continued after surgery is considered a single regimen. Hormonal therapy is not considered to be a chemotherapy regimen.
•The most recent treatment regimen need not be a platinum-containing or a taxane containing regimen.
•Prior therapy cannot include more than 2 prior taxane-containing regimens.
•4. Current use of tamoxifen, thalidomide, or any agent used as maintenance or consolidation therapy for OC.
•5. Known hypersensitivity to Cremophor® EL, paclitaxel, or its components.
•6. Prior history of = Grade 2 neurotoxicity or any toxicity requiring discontinuation from taxane chemotherapy that is not resolved to = Grade 1.
•7. Any comorbid condition or unresolved toxicity that would preclude administration of weekly paclitaxel.
•8. Diagnosis of primary CNS malignancy or carcinomatous meningitis.
•9. Patient has symptomatic brain metastasis. Patients with brain metastases must:
•Have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy; and
•Be without neurologic dysfunction that would confound the evaluation of neurologic and other AEs.
•10. Inability to swallow PO administered medications or to maintain a fast as required before and after alisertib administration.
•11. History of hemorrhagic or thrombotic cerebrovascular event in the past 12 months.
•12. Surgery within 3 weeks before study enrollment and not fully recovered to baseline or to a stable clinical status.
•13. Diagnosis of or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type, including patients with Stage IA or IB endometrioid carcinomas, are not excluded if they have undergone complete resection.
•14. Patients who are lactating or have a positive serum pregnancy test during the screening period.
•15. Other severe acute or chronic medical or psychiatric condition, including uncontrolled diabetes, malabsorption, resection of the pancreas or upper small bowel, requirement for pancreatic enzymes, any condition that would modify small bowel absorption of oral medications, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate

研究者

发起方

Millennium Pharmaceuticals, Inc

相似试验

进行中（未招募）

不适用

A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaPlatinum-refractory and platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomaMedDRA version: 11.1Level: LLTClassification code 10033131Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10016180Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10052171Term: <Manually entered code. Term in E.1.1>

EUCTR2008-006979-72-PLMillennium Pharmaceuticals, Inc56

进行中（未招募）

1 期

EUCTR2008-006979-72-FRMillennium Pharmaceuticals, Inc31

进行中（未招募）

1 期

A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic SyndromeAcute myelogenous leukemia (AML) and high-grade myelodysplastic syndrome (MDS)MedDRA version: 11.1Level: LLTClassification code 10028533Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10000886Term: <Manually entered code. Term in E.1.1>

EUCTR2008-006977-34-FRMillennium Pharmaceuticals, Inc.57

进行中（未招募）

不适用

A study of MLN8237 in patients with solid tumor cancers to find the highest does of MLN8237 followed by further investigation of that dose in cancers of the lung, breast, head and neck or the gastic/oesphagus region.Phase I portion of the study - Advanced nonhematologic malignancies.Phase II portion of the study - Non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), adenocarcinoma of the esophagus/gastroesophageal junction or stomach, head and neck carcinoma, or adenocarcinoma of the breast.MedDRA version: 16.0Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: LLTClassification code 10006173Term: Breast adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2008-006981-27-CZMillennium Pharmaceuticals, Inc270

已完成

2 期

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate CancerSmall Cell Prostate CancerNeuroendocrine Prostate CancerProstate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers

NCT01799278Weill Medical College of Cornell University60